The Latest Cardiac and Vascular News
BOSTON, Aug. 29, 2022 /PRNewswire/ — CereVasc, Inc., a privately held, clinical-stage, medical device company developing novel, minimally invasive treatments for neurological diseases, announced completion of the first eShunt® procedure in the United States. The study, ‘US Pilot Study of the CereVasc eShunt System in Normal Pressure Hydrocephalus (NPH)’, is being conducted under an investigational device […]
US Based Pilot Study to enroll patients who develop communicating hydrocephalus following subarachnoid hemorrhage BOSTON, Aug. 9, 2022 /PRNewswire/ — CereVasc, Inc., a privately held, clinical-stage, medical device company developing novel, minimally invasive treatments for neurological diseases, announced today that the U.S. Food and Drug Administration (FDA) has approved an investigational device exemption […]
BOSTON, Feb. 8, 2022 /PRNewswire/ — CereVasc, Inc., a privately held, clinical-stage, medical device company developing novel, minimally invasive treatments for neurological diseases, announced today that the U.S. Food and Drug Administration (FDA) has approved an investigational device exemption (IDE) application to initiate a pilot trial of the eShunt System in patients […]
Case represents the first time hydrocephalus has been successfully treated using a minimally-invasive endovascular procedure BOSTON, Dec. 7, 2021 /PRNewswire/ — CereVasc, Inc., a clinical-stage, medical device company developing novel, minimally invasive treatments for neurological diseases, announced today the publication of a case report detailing the first treatment in a study of […]
Investigational device has the potential to transform a half-century-old standard of care BOSTON, Feb. 10, 2021 /PRNewswire/ — CereVasc, Inc., a clinical-stage, medical device company developing novel, minimally invasive treatments for neurological diseases, has treated the first patient in a study of its eShunt System, an investigational device intended to treat communicating […]
